Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Assets (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Non-Current Assets for 13 consecutive years, with $33000.0 as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 96.6% year-over-year to $33000.0; the TTM value through Mar 2026 reached $1.7 million, down 61.39%, while the annual FY2025 figure was $131000.0, 88.14% down from the prior year.
  • Non-Current Assets hit $33000.0 in Q1 2026 for Viking Therapeutics, down from $131000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.7 million in Q1 2022 and bottomed at $33000.0 in Q1 2026.
  • Average Non-Current Assets over 5 years is $1.1 million, with a median of $1.2 million recorded in 2024.
  • Year-over-year, Non-Current Assets surged 1011.19% in 2022 and then tumbled 96.6% in 2026.
  • Viking Therapeutics' Non-Current Assets stood at $1.5 million in 2022, then fell by 15.04% to $1.3 million in 2023, then dropped by 12.65% to $1.1 million in 2024, then plummeted by 88.14% to $131000.0 in 2025, then tumbled by 74.81% to $33000.0 in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $33000.0, $131000.0, and $712000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.